TAVABOROLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TAVABOROLE (TAVABOROLE).
Tavaborole is a boron-containing antifungal agent that inhibits fungal protein synthesis by trapping leucyl-tRNA synthetase in a closed conformation via formation of a boron adduct with the tRNA(Leu) in the editing site, leading to accumulation of mischarged tRNA and inhibition of protein synthesis.
| Metabolism | Tavaborole undergoes minimal systemic metabolism; the primary metabolic pathway is oxidation via CYP450 enzymes (CYP3A4, CYP2C19, CYP2E1) to form inactive hydroxylated metabolites, followed by glucuronidation. |
| Excretion | Approximately 80% of a dose is excreted in feces as unchanged drug and metabolites, with less than 10% excreted in urine. Biliary excretion is the primary route for elimination of parent drug and metabolites. |
| Half-life | The terminal elimination half-life is approximately 130–140 hours (about 5.5–6 days) in patients with onychomycosis, supporting a once-weekly dosing regimen. This long half-life allows drug accumulation in the nail plate. |
| Protein binding | Tavaborole is highly bound to plasma proteins (approximately 92–95%), primarily to albumin. |
| Volume of Distribution | The apparent volume of distribution is large (approximately 450–600 L) indicating extensive tissue distribution, particularly into the nail plate and keratinous tissues. Weight-based calculation not routinely reported; typical Vd exceeds total body water. |
| Bioavailability | Topical bioavailability is negligible (<1% of the applied dose) after application to toenails, as the drug is designed to penetrate the nail plate with minimal systemic absorption. Systemic exposure is low and proportional to dose. |
| Onset of Action | The onset of clinical effect is delayed; visible improvement of onychomycosis typically requires several months due to the time for healthy nail growth. Serum concentrations reach steady state after approximately 4–6 weeks of once-weekly dosing. |
| Duration of Action | After completion of treatment (e.g., 12 weeks), drug levels in the nail plate persist for months due to slow clearance, providing a prolonged duration of action that contributes to efficacy even after therapy ends. |
3 mg applied topically once daily to the affected areas on the face and/or trunk as a thin layer.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Approved for ages 9 years and older. Apply 3 mg topically once daily to affected areas. Safety and efficacy in children under 9 years not established. |
| Geriatric use | No specific dose adjustment required; clinical studies included limited number of patients aged 65 and older, no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TAVABOROLE (TAVABOROLE).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Based on molecular weight (420.3 Da), excretion is possible. Use during breastfeeding only if clearly needed, with monitoring for adverse effects in the infant. |
| Teratogenic Risk | No human data; animal studies show no evidence of teratogenicity at exposures up to 3 times the human AUC. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: avoid unless necessary. Second and third trimesters: limited data, no known specific fetal risks. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to tavaborole or any component of the formulation."]
| Precautions | ["For external use only; avoid contact with eyes and mucous membranes.","Discontinue if signs of hypersensitivity or local skin irritation occur.","Not studied in immunocompromised patients or those with severe peripheral vascular disease.","Use during pregnancy only if potential benefit justifies potential risk to the fetus (no adequate human data)."] |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required; standard prenatal care. Monitor for maternal hepatic function if prolonged therapy. |
| Fertility Effects | No effect on fertility in animal studies at clinical exposures. Human data lacking, but no expected impact. |